Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Jenkins

Showing results (131-140 of 269) with videos related to

Pageof 27
Sort By:
Genes, Chromosomes & Cancer|April 27, 2016
PPP6R3-USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitisRuifeng Guo, Xiaoke Wang, Margaret M Chou, et al.
Neuro-Oncology|October 18, 2017
Molecular subtyping of tumors from patients with familial gliomaVanessa Y Ruiz, Corinne E Praska, Georgina Armstrong, et al.
Neurology|December 19, 2025
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort StudyMuhammad Asad Maqbool, Robert B Jenkins, Cristiane M Ida, et al.
Clinical Breast Cancer|December 31, 2005
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252Edith A Perez, Vera J Suman, Kendrith M Rowland, et al.
Cancer Research|July 5, 2002
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumorsColleen S Sinclair, Camilo Adem, Ali Naderi, et al.
Breast Cancer Research and Treatment|March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancerAlvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
BMC Genomics|October 22, 2016
Impact of RNA degradation on fusion detection by RNA-seqJaime I Davila, Numrah M Fadra, Xiaoke Wang, et al.
Neuro-Oncology Advances|February 27, 2023
Genomic markers of recurrence risk in atypical meningioma following gross total resectionRachael A Vaubel, Rahul Kumar, Taylor M Weiskittel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Genes, Chromosomes & Cancer|May 5, 2018
Copy number variant analysis using genome-wide mate-pair sequencingJames B Smadbeck, Sarah H Johnson, Stephanie A Smoley, et al.
Pageof 27

Showing results (131-140 of 269) with videos related to

Sort By:
Pageof 27
Genes, Chromosomes & Cancer|April 27, 2016
PPP6R3-USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitisRuifeng Guo, Xiaoke Wang, Margaret M Chou, et al.
Neuro-Oncology|October 18, 2017
Molecular subtyping of tumors from patients with familial gliomaVanessa Y Ruiz, Corinne E Praska, Georgina Armstrong, et al.
Neurology|December 19, 2025
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort StudyMuhammad Asad Maqbool, Robert B Jenkins, Cristiane M Ida, et al.
Clinical Breast Cancer|December 31, 2005
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252Edith A Perez, Vera J Suman, Kendrith M Rowland, et al.
Cancer Research|July 5, 2002
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumorsColleen S Sinclair, Camilo Adem, Ali Naderi, et al.
Breast Cancer Research and Treatment|March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancerAlvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
BMC Genomics|October 22, 2016
Impact of RNA degradation on fusion detection by RNA-seqJaime I Davila, Numrah M Fadra, Xiaoke Wang, et al.
Neuro-Oncology Advances|February 27, 2023
Genomic markers of recurrence risk in atypical meningioma following gross total resectionRachael A Vaubel, Rahul Kumar, Taylor M Weiskittel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Genes, Chromosomes & Cancer|May 5, 2018
Copy number variant analysis using genome-wide mate-pair sequencingJames B Smadbeck, Sarah H Johnson, Stephanie A Smoley, et al.
Pageof 27